Our study demonstrates an incidence rate of 5.7% for infliximab and 0.6% for adalimumab, which are much higher than postmarketing studies.8 This corresponds to a retrospective study in an IBD population, which identified 20 of 289 patients (6.9%) on anti‐TNF therapy who developed a lupus‐like reaction.9 This evidence concerns the gene TNF and inflammatory bowel disease.